Celgene Corp. has described heterocyclic protein-arginine deiminase type-4 (PADI4) inhibitors reported to be useful for the treatment of aging, autoimmune diseases, pain, asthma, inflammatory bowel diseases, AIDS, cancer and Alzheimer's disease, among others.

Samdolite Pharmaceuticals LLC has divulged prodrugs of cromoglicic acid reported to be useful for the treatment of inflammation and dermatological disorders.

Sperogenix Therapeutics Ltd. has identified nitrogen-containing five-membered heterocyclic derivatives acting as checkpoint kinase 1 (Chk1) inhibitors reported to be useful for the treatment of cancer, idiopathic pulmonary fibrosis and pulmonary arterial hypertension.

858 Therapeutics Inc. has disclosed poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of cancer.

Shanghai Meiyue Biotech Development Co. Ltd. has identified serine/threonine-protein kinase SIK2 (QIK) inhibitors reported to be useful for the treatment of fibrosis, cancer, autoimmune diseases, transplant rejection, cardiovascular, dermatological, endocrine, and inflammatory disorders, among others.

Hangzhou Healthytide Biotechnology Co. Ltd. has synthesized peptoids acting as integrin α5β1 (ITGA5; VLA-5) antagonists reported to be useful for the treatment of cancer and macular degeneration.

Dice Alpha Inc. has disclosed IL-17A inhibitors reported to be useful for the treatment of psoriasis, radiographic axial spondyloarthritis (ankylosing spondylitis), hidradenitis suppurativa, spondyloarthritis, psoriatic and rheumatoid arthritis.

Xalud Therapeutics Inc. has described conjugates comprising a sugar moiety covalently bonded to a DNA-interacting moiety through a linker reported to be useful for the treatment of pain, inflammation and autoimmune diseases, among others.

Cypralis Ltd. has divulged macrocyclic compounds acting as peptidyl-prolyl cis-trans isomerase A (PPIA; cyclophilin A; CYPA) and/or cyclophilin D inhibitors reported to be useful for the treatment of multiple sclerosis and epilepsy.

Zhejiang Wenda Pharma Technology Ltd. has identified HER2 (erbB2) and its (exon 20 insertion [Ex20Ins], (Ala775_Gly776insTyrValMetAla)) mutant inhibitors reported to be useful for the treatment of cancer.